Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Lenvatinib in locally advanced HCC
NCT04042805Phase 2Unknown
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04042805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042805.